Latest news is provided by our trusted partners at MJH Life Sciences® and its brands, and is not a publication of NCOA.
November 18, 2026
OncLive Staff
Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.
Ryan Kret
Maintenance galinpepimut-S extended overall survival in transplant-ineligible AML in second or later remission.
Longer follow-up of KANDLELIT-001 supports frontline calderasib plus pembrolizumab in KRAS G12C–mutated metastatic non–small cell lung cancer.
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
November 17, 2026
Chris Ryan
The FDA removed the PCNSL limitation of use from the liso-cel label in LBCL, making it the second CAR T-cell therapy with this update.
Christine Ann Garcia, MD, MPH, discusses error review in fellowship training, survivorship in EGFR+ lung cancer, and nontraditional career paths.
Sanjiv Gangaram-Panday, MD, PhD, discusses 5-year SANO outcomes, distant dissemination, and next steps for active surveillance in esophageal cancer.
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.
The FDA accepted an sNDA for selinexor plus ruxolitinib in myelofibrosis, with a target action date of June 28, 2027.
Riley Kandel
The FDA has approved neladalkib for previously treated, ALK-positive, locally advanced or metastatic non-small cell lung cancer.
Roswell Park Comprehensive Cancer Center
Roswell Park researchers found CD83 CAR T cells could overcome CD19-targeted therapy resistance in preclinical models of B-cell cancers.
Sidharth Rastogi
Ryan J. Sullivan, MD, discusses HLA testing, liver-directed therapy, and emerging targeted and T-cell–based therapies for metastatic uveal melanoma.
November 16, 2026
Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.
The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.
Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.